Forecasts indicate that the worldwide congenital hyperinsulinism treatments market size is predicted to reach US$ 100 million by 2023 and increase at a Compound Annual Growth Rate (CAGR) of 6% from 2023 to 2033, reaching a market value of US$ 179.08 million. With a CAGR of 4%, the market performed well between 2017 and 2022. …